Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Health, Republic of Korea | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pazopanib + conventional chemotherapy | Experimental | Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pazopanib | Drug | Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Tolerated Dose (MTD) of Pazopanib in combination chemotherapy | Definition of dose-limiting toxicity (DLT)
| 42 days |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of tumor response (neuroblastoma) |
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ki Woong Sung, MD, PhD | Contact | 82-2-3410-3529 | kiwoong.sung@samsung.com |
| Name | Affiliation | Role |
|---|---|---|
| Ki Woong Sung, MD, PhD | Samsung Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| C516667 | pazopanib |
| D007069 | Ifosfamide |
| D016190 | Carboplatin |
| D005047 | Etoposide |
| ID | Term |
|---|---|
| D003520 | Cyclophosphamide |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ifosfamide | Drug | Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib |
|
| Carboplatin | Drug | Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib |
|
| Etoposide | Drug | Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib |
|
| 4 weeks |
| Rate of tumor response (brain tumor) | - as assessed by 2-dimensional measurement (the product of the tumor's longest diameter and its longest perpendicular diameter)
| 4 weeks |
| Rate of tumor response (other solid tumors) | - as assessed by The Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
| 4 weeks |
| D006846 |
| Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D010078 | Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D056831 | Coordination Complexes |
| D011034 | Podophyllotoxin |
| D013764 | Tetrahydronaphthalenes |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D011083 | Polycyclic Compounds |
| D005960 | Glucosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |